OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Ovarian cancer responds to Aspirin derivative with Cisplatin


A study using ovarian cancer cell lines showed promise in treating tumor by combining the chemotherapy drug Cisplatin with an Aspirin-like compound to make recurrent cancer cells less resistant to the chemotherapy.

The study is published in the Proceedings of the National Academy of Sciences ( PNAS ).

As a first course of treatment, ovarian cancer typically is treated with surgery followed by a regimen of the chemotherapy drug Cisplatin.
However, Cisplatin is not an effective treatment when the ovarian cancer inevitably returns, says Periannan Kuppusamy, at the Ohio State University Comprehensive Cancer Center.

" Somehow the ovarian cancer cells adapt and become resistant to this drug," said Kuppusamy, lead author of the study. " Once treated with Cisplatin, the ovarian cancer cells develop an abundance of thiols, which are a kind of cellular antioxidants that protect the cancer from the chemotherapy."

Kuppusamy wondered whether the abundance of thiols could somehow be used against the ovarian cancer cells. The study found that the nitric oxide released from the Aspirin derivative NCX-4016 reacts with the cellular thiols, which causes the cancer cells to stop proliferating. In addition, the nitric oxide depletes the thiols, making the cancer cells more susceptible to the chemotherapy.

" The nitric oxide-releasing ability of the aspirin derivative NCX-4016 is enhanced by thiols, so I thought this type of treatment might work better in a tumor cancer cell that is rich in thiols, such as a resistant ovarian cancer," Kuppusamy said.

Source: Ohio State University, 2006


XagenaMedicine_2006



Indietro